THE USE OF RIVANOL TREATMENT FOR REMOVAL FROM SERA OF NONSPECIFIC INHIBITORS OF ENTEROVIRUS AND REOVIRUS HEMAGGLUTINATION1

Publisher Website
Google Scholar
Abstract
Styk, B., N. J. Schmidt (Viral and Rickettsial Disease Lab., Calif. State Dept. of Public Health, Berkeley, Calif. 94704) and J. Dennis. The use of rivanol treatment for removal from sera of nonspecific inhibitors of enterovirus and reovirus hemag-glutination. Amer. J. Epid., 1968, 88: 398–405—Rivanol treatment was found to be a highly effective method for removal of nonspecific inhibitors of hemagglutination by echoviruses, group B coxsackieviruses and reovirus type 1 from human and immune monkey sera. Although rivanol precipitation is known to remove IgM immunoglobulins from sera, it was found that specific hemagglutination-inhibiting antibody levels, even in sera collected early in the course of infection, were decreased little or not at all by rivanol treatment. Antibody titers of early sera were generally reduced to a greater extent by treatment with 2-mercaptoethanol than by rivanol treatment. The use of excessive amounts of charcoal to remove residual rivanol from treated sera was found to adsorb some specific antibody. A simplified procedure for rivanol treatment of sera is described, which makes the technic feasible for use in the diagnostic laboratory and for large-scale epidemiologic studies.

This publication has 0 references indexed in Scilit: